ONCOLOGY® Companion, Volume 35, Supplement 2

D. Ross Camidge, MD, PhD, and Alexander I. Spira, MD, PhD, discussed the use of NRG1 fusions as being a driver for patients with lung cancer.

Richard Kim, MD, and Lilliana Bustamante, MD, discuss the potnetial for using ctDNA to treat patients with oligometastatic colorectal cancer.

A. Oliver Sartor, MD, discussen treatment options for PARP inhibitor use in patients with prostate cancer.

Zofia Piotrowska, MD, discusses potential therapies for patients with EGFR exon 20 insertion-positive non–small cell lung cancer.

A panel of experts reflect on how to treat patients with advanced renal cell carcinoma by reviewing clinical trial data and discussing patient cases.

Recommendations for treating patients with steroid-refractory chronic GVHD based on evidence demonstrated by the REACH3 trial.

A panel of experts discuss strategies for optimizing first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma.

Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.